In conclusion, our study identifies AKBA as a novel and potent MGLL inhibitor and suggests that it holds promise as a therapeutic candidate for NAFLD and related metabolic diseases. This evidence concerns the gene MGLL and metabolic dysfunction-associated steatotic liver disease.